Jinling Hospital, China
Clinical trials sponsored by Jinling Hospital, China, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for kidney cancer: Real-World study tests vorolanib as Second-Line therapy Results expected Sep 2026 (estimated)
- Wrist vs groin: which artery route is best for stroke clot removal? Results expected Sep 2026 (estimated)
- New rad combo targets kidney cancer after immunotherapy fails Results expected Sep 2026 (estimated)
- Could a common bile acid pill shield kidneys during cancer surgery? Results expected Oct 2026 (estimated)
- New hope for liver cancer patients: 4-drug combo targets untreatable tumors Results expected Nov 2026 (estimated)
-
Kidney cancer drug combo trial stopped early – what happened?
Disease control Stopped earlyThis study tested two drugs (toripalimab and lenvatinib) given before and after kidney cancer surgery in people with different stages of kidney cancer. The goal was to see if the treatment could shrink or eliminate the tumor before surgery and keep cancer from coming back after. …
Phase 2 • Sponsor: Jinling Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Can two diabetes drugs save kidneys after cancer surgery?
Disease control Stopped earlyThis study looked at whether two drugs, finerenone and empagliflozin, can slow kidney function decline in people at high risk for chronic kidney disease after having a kidney removed for cancer. Ten participants took one or both drugs or no drug for a year. The trial was terminat…
Phase 2 • Sponsor: Jinling Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC